Author/Authors :
Çermik, Tevfik Fikret University of Health and Sciences Turkey - İstanbul Training and Research Hospital - Clinic of Nuclear Medicine - İstanbul, Turkey , Arslan, Esra University of Health and Sciences Turkey - İstanbul Training and Research Hospital - Clinic of Nuclear Medicine - İstanbul, Turkey , Aksoy, Tamer University of Health and Sciences Turkey - İstanbul Training and Research Hospital - Clinic of Nuclear Medicine - İstanbul, Turkey , Cin, Merve University of Health and Sciences Turkey - İstanbul Training and Research Hospital - Department of Pathology - İstanbul, Turkey , Çakır, Coşkun University of Health and Sciences Turkey - İstanbul Training and Research Hospital - Clinic of Surgery - Istanbul, Turkey , Trabulus, Fadime Didem Can University of Health and Sciences Turkey - İstanbul Training and Research Hospital - Clinic of Surgery - Istanbul, Turkey
Abstract :
A 67-year-old male patient had undergone total gastrectomyand Roux-en-Y eso-jejunostomy 3 years ago for the treatment of tubular adenocarcinoma located at the corpus of the stomach. The patient was diagnosed with Gleason score 8 (4+4) metastatic prostate cancer during the follow-up period and received hormone therapy. Owing to his elevated prostate-specific antigen levels (77 ng/mL), his clinician referred him gallium-68 (68Ga) prostate-specific membrane antigen 11 (PSMA) positron emission tomography/computed tomography (PET/CT) for restaging. PET/CT showed multiple 68Ga PSMA receptor-positive skeletal lesions and linear PSMA activity at the eso-jejunostomy junction. He was then referred to undergo 18fluorine-fluorodeoxyglucose (18F-FDG) PET/CT to screen for gastric carcinoma recurrence.PET/CT images demonstrated no 18F-FDG avid lesion. However, endoscopy and biopsy performed with samples from the eso-jejunostomy junction revealed superficial benign squamous epithelial fragments.
Keywords :
prostate carcinoma , gastric carcinoma , PET/CT , 18F-FDG , 68Ga-PSMA
